Verve Therapeutics appoints Jodie Morrison and Vertex exec Nia Tatsis to board

Verve Therapeutics, Inc.

Board expanded to nine members; Morrison (Class I, term to 2025) and Tatsis (Class III, term to 2027) elected June 26, 2024.
Morrison is independent; Tatsis is an executive officer of Vertex, Verve's collaborator under a 2022 strategic deal.
Each new director received an option for 267,541 shares at $5.02 per share, vesting over three years.
Tatsis's appointment deepens ties with Vertex, which paid Verve $25M upfront and up to $406M in milestones and royalties.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jodie Morrison

Director

Verve Therapeutics, Inc.

Effective: 2024-06-26
Filed: June 28, 2024, 7:59 PM ET

elected, effective immediately, Jodie Morrison as a member of the Board

Appointed

Ourania "Nia" Tatsis, Ph.D.

Director

Verve Therapeutics, Inc.

Effective: 2024-06-26
Filed: June 28, 2024, 7:59 PM ET

Ourania "Nia" Tatsis, Ph.D. as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jodie Morrison was elected as Director at Verve Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

elected, effective immediately, Jodie Morrison as a member of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ourania "Nia" Tatsis, Ph.D. was elected as Director at Verve Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

Ourania "Nia" Tatsis, Ph.D. as a member of the Board

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-171310

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.